de Jong, Anouk C. http://orcid.org/0000-0002-7381-3171
Danyi, Alexandra http://orcid.org/0000-0002-1857-0816
van Riet, Job http://orcid.org/0000-0001-7767-7923
de Wit, Ronald
Sjöström, Martin http://orcid.org/0000-0002-2629-9966
Feng, Felix http://orcid.org/0000-0002-0963-7687
de Ridder, Jeroen http://orcid.org/0000-0002-0828-3477
Lolkema, Martijn P. http://orcid.org/0000-0003-0466-2928
Funding for this research was provided by:
Johnson and Johnson (212082PCR3014)
Astellas Pharma US (Lolkema/NL-72-RG-11)
Article History
Received: 9 September 2022
Accepted: 22 March 2023
First Online: 8 April 2023
Competing interests
: RdW has speaker/advisory roles at Sanofi, Bayer, and Astellas, advisory roles at Orion, Hengrui, and Merck US, and received institutional research grants from Sanofi and Bayer. FF received personal fees as a consultant for Janssen, Myovant, Roivant, Novartis, Astellas, Foundation Medicine and Exact Sciences, as a member of the scientific advisory board of Bayer, SerImmune, Bristol Meyers Squibb (BMS), Bluestar Genomics, Blue Earth Diagnostics, and Tempus, as an advisor with stock options at Artera, and as former co-founder with ownership interests of PFS Genomics (relationship termed in April 2021. JdR is co-founder of Cyclomics BV. ML received advisory role/speaker fees from Incyte, Amgen, Janssen Cilag B.V., Bayer, Servier, Roche, Pfizer, Sanofi Aventis Netherlands BV, and Astellas, and has received institutional research funding from Sanofi, JnJ, Merck, and Astellas. All other authors declare no competing interests.